How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

640 results for

aspirin

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials

Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

62. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials

Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

63. Antifibrinolytics in cardiac surgical patients receiving aspirin: a systematic review and meta-analysis

Antifibrinolytics in cardiac surgical patients receiving aspirin: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

64. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

65. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials

Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

66. The effect of aspirin in the recurrence of colorectal adenomas: a meta-analysis of randomized controlled trials

The effect of aspirin in the recurrence of colorectal adenomas: a meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

67. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force

Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force Wolff T, Miller T, Ko S Record Status This is a bibliographic record of a published health technology (...) assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Synthesis No 68. 2009 Authors' objectives To determine the benefits and harms of taking aspirin for the primary prevention of myocardial infarctions

2009 Health Technology Assessment (HTA) Database.

68. Cardiovascular Disease: Tailored Pharmacy-based Interventions to Improve Medication Adherence

. Search Strategy – Effectiveness Review Database: PubMed #1 "Hypertension"[Mesh] OR "Blood Pressure"[Mesh] OR "Hypercholesterolemia"[Mesh] OR "Cholesterol"[Mesh] OR "Aspirin"[Mesh] OR "hypertension"[Title/Abstract] OR "blood pressure"[Title/Abstract] OR "cholesterol"[Title/Abstract] OR "hypercholesterol"[Title/Abstract] OR "hypercholesterolemia"[Title/Abstract] OR “acetylsalicylic acid”[Title/Abstract] or “ASA”[Title/Abstract] OR “aspirin"[Title/Abstract] OR "high blood pressure" OR "high cholesterol (...) disease).mp. 36. (thromboembolic disease or congestive heart failure or atherosclerosis).mp. 37. or/28-36 38. 8 and 21 and 22 and 27 39. 7 and 21 and 22 and 27 and 37 40. limit 38 to english language 41. limit 39 to english language 42. 40 or 41 Database: Scopus #1 TITLE-ABS-KEY ( "Hypertension" OR "Blood Pressure" OR "Cholesterol" OR " hypercholesterol*” OR "aspirin" OR “acetylsalicylic acid” or “ASA” OR "high lipid levels" OR "high level lipids" OR "blood fat" OR "blood fats" OR "blood lipid

2020 Publication 4890974

69. [SHINSA]English Translation of Review Report: Zagallo

2015 Sunvepra asunaprevir July 2014 Symproic naldemedine tosilate March 2017 Synflorix pneumococcal 10-valent conjugate vaccine adsorbed (non-typeable haemophilus influenzae [NTHi] protein D, diphtheria or tetanus toxoid conjugates) March 2015 T Name Active Ingredient Approved In PDF EN PDF JP Tafinlar dabrafenib mesilate March 2016 Tagrisso osimertinib mesilate March 2016 Takecab vonoprazan fumarate December 2014 Takelda aspirin/lansoprazole March 2014 Talion bepotastine besilate May 2015 Taltz

2019 Pharmaceuticals and Medical Devices Agency, Japan

70. TNF-α blockers for the treatment of Kawasaki disease in children. (Abstract)

TNF-α blockers for the treatment of Kawasaki disease in children. Kawasaki disease (KD) is an acute inflammatory vasculitis (inflammation of the blood vessels) that mainly affects children between six months and five years of age. The vasculitis primarily impacts medium-sized blood vessels, especially in the coronary arteries. In most children, intravenous immunoglobulin (IVIG) and aspirin therapy rapidly reduce inflammatory markers, fever, and other clinical symptoms. However, approximately 15

2019 Cochrane

71. Medical interventions for traumatic hyphema. Full Text available with Trip Pro

), cycloplegics, miotics, aspirin, conjugated estrogens, traditional Chinese medicine, monocular versus bilateral patching, elevation of the head, and bed rest.We found no evidence of an effect on visual acuity for any intervention, whether measured within two weeks (short term) or for longer periods. In a meta-analysis of two trials, we found no evidence of an effect of aminocaproic acid on long-term visual acuity (RR 1.03, 95% confidence interval (CI) 0.82 to 1.29) or final visual acuity measured up (...) with no use, but this outcome was not altered by any other intervention.The available evidence on usage of systemic or topical corticosteroids, cycloplegics, or aspirin in traumatic hyphema was limited due to the small numbers of participants and events in the trials.We found no evidence of an effect between a single versus binocular patch or ambulation versus complete bed rest on the risk of secondary hemorrhage or time to rebleed.We found no evidence of an effect on visual acuity by any

2019 Cochrane

72. Expansion of MBS item 73325 to include additional populations and mutations beyond those currently specified (for the characterisation of JAK2 or MPL genes)

of myeloproliferative disorders (Figure 1). Figure 1 Diagnostic workup of myeloproliferative disorders Source: Contracted Assessment for MSAC Application 1532. Figure A6.1 p, 14. The CA stated that treatment for PV, ET and PMF is based upon the patient’s risk. In ET, patients aged over 60 years with JAK2 mutations are considered at high risk, and are recommended for treatment with cytoreductive therapy if response to aspirin, hydroxyurea, interferons or anagrelide is inadequate. 7 9. Comparator The CA provided

2019 Medical Services Advisory Committee

73. Care prior to and during subsequent pregnancies following stillbirth for improving outcomes. Full Text available with Trip Pro

interventions; no trials assessed psychosocial interventions or incorporated psychosocial aspects of care. Trials evaluated the use of antiplatelet agents (low-dose aspirin (LDA) or low-molecular-weight heparin (LMWH), or both), third-party leukocyte immunisation, intravenous immunoglobulin, and progestogen. Trial participants were women who were either pregnant or attempting to conceive following a pregnancy loss, fetal death, or adverse outcome in a previous pregnancy.We extracted data for 222 women who

2018 Cochrane

74. Continuation versus discontinuation of antiplatelet therapy for bleeding and ischaemic events in adults undergoing non-cardiac surgery. Full Text available with Trip Pro

included five RCTs with 666 randomized adults. We identified three ongoing studies.All study participants were scheduled for elective general surgery (including abdominal, urological, orthopaedic and gynaecological surgery) under general, spinal or regional anaesthesia. Studies compared continuation of single or dual antiplatelet therapy (aspirin or clopidogrel) with discontinuation of therapy for at least five days before surgery.Three studies reported adequate methods of randomization, and two

2018 Cochrane

77. Ticagrelor for preventing thrombotic events in adults with acute coronary syndromes

in combination with low-dose aspirin for up to 12 months. Subsidy status Ticagrelor 90 mg tablet is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications. MAF assistance does not apply to the ticagrelor 60 mg tablet. Factors considered to inform the recommendations for subsidy Technology evaluation Point Item 1.1 The MOH Drug Advisory Committee ("the Committee") considered the evidence presented for the technology evaluation of ticagrelor for preventing (...) considerations. 1.4 The manufacturer of ticagrelor, which was not recommended for subsidy in 2017 because of unacceptable cost-effectiveness, was invited to submit a revised price proposal, which the Committee considered in August 2018. Clinical need Point Item 2.1 Dual anti-platelet therapy with a P2Y 12 -receptor antagonist (such as ticagrelor or clopidogrel) in combination with maintenance low-dose aspirin for at least 12 months is considered by local cardiologists as the standard of care for ACS, in line

2019 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

79. Bioresorbable Stents in cardiovascular indications (coronary artery disease)

with an immunosuppressant or cytotoxic drug. A polymer coating is usually used for drug loading and control of elution kinetics. Sustained release of the drug reduces neointimal hyperplas- ia, leading to a reduction in the rate of restenosis. However, because stent implantation can also lead to stent thrombosis with potentially deleterious consequences, it necessitates potent antiplate- let therapy with a combination of aspirin and P2Y12 inhibitors, thus leading to potential bleeding complications. A consequence

2019 EUnetHTA

Systematic Reviews (Non-Premium)

Systematic reviews are arguably the most important way of telling if an intervention is worthwhile.  As a FREE user you have access to 100,000 less systematic reviews than a Pro user.  Upgrade today.